Witnessing a revolution in the vaccinology field: A thought on its probable impact on future vaccines

Document Type : Commentary-Article

Authors

1 Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

10.30476/tips.2022.94005.1131

Abstract

Vaccines have been one of the most remarkable achievements through medical history and have had a very high positive impact on human health (1). The number of prevented deaths through vaccination is estimated to be about 2-3 million per year (2). Reduction of the risk of many infectious diseases and eradication of smallpox have been the result of intensive immunization programs (3). Given that such health benefits are also translated to economic advantages, the indirect positive outcomes of immunization could be very broad. For instance, lost working days due to different diseases could partly be prevented through vaccination. Thus, despite the huge investments needed for immunization programs, they are usually assumed as cost-effective projects (4). 
Please cite this article as: Manica Negahdaripour, Younes Ghasemi. Witnessing a revolution in the vaccinology field: A thought on its probable impact on future vaccines. Trends in Pharmaceutical Sciences. 2022;8(2):67-68. 
doi: 10.30476/TIPS.2022.94005.1131

Keywords


1.    Negahdaripour M, Golkar N, Hajighahramani N, Kianpour S, Nezafat N, Ghasemi Y. Harnessing self-assembled peptide nanoparticles in epitope vaccine design. Biotechol Adv. 2017;35:575-96.
2.    Echeverria-Londono S, Li X, Toor J. et al. How can the public health impact of vaccination be estimated? BMC Public Health. 2021;21:2049. 
3.    Almond J, Hacker J, Harwood C, Pizza M, Rappuoli R, Ron EZ, Sansonetti P, Vanderslott S, Wieler LH. Development of vaccines at the time of COVID-19. Microlife. 2020;1:uqaa003.
4.    Rodrigues Charlene MC, Plotkin Stanley A, Impact of Vaccines; Health, Economic and Social Perspectives. Front Microbiol. 2020;11:1526. 
5.    Han S. Clinical vaccine development. Clin Exp Vaccine Res 2015; 4(1): 46-53.
6.    Negahdaripour M, Shafiekhani M, Moezzi SMI, Amiri S, Rasekh S, Bagheri A, Mosaddeghi P, Vazin A. Administration of COVID-19 vaccines in immunocompromised patients. Int Immunopharmacol. 2021;99:108021.
7.    Pulendran B, Rappuoli R. Editorial overview: Vaccines 2020. Curr Opin Immunol. 2020;65:iii. 
8.    Negahdaripour M. COVID-19 Vaccine Global Access Is an Urgency. Iran J Med Sci. 2021;46:79–80. 
9.    Kremer EJ, Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines. Mol Ther. 2020;28:2303-2304.